# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 131-140 of 2220 results.
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
Status: Withdrawn
Last Changed: May 23, 2017
First Received: Nov 03, 2015
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Cyclophosphamide, Vincristine, Prednisone
Locations: Tianjin people's Hospital, Tianjin, China
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status: Terminated
Last Changed: May 09, 2017
First Received: Jan 25, 2011
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Panobinostat with Rituximab
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
Status: Completed
Last Changed: Sep 23, 2016
First Received: Mar 16, 2012
Disease(s): Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
Intervention(s): Lenalidomide
Locations: CHU Amiens, Hôpital Sud, Amiens, France
CHU Besançon, Hôpital Saint-Jacques, Besançon, France
AP-HP Hôpital Avicenne, Bobigny, France
AP-HP Hôpital Ambroise Paré, Boulogne-billancourt, France
CHU de Clermont-Ferrand, Estaing, Clermont-ferrand, France
... and 20 other locations.
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma
Status: Completed
Last Changed: Jan 22, 2019
First Received: Sep 17, 2007
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Autologous Blood Stem Transplantation, R-CHOP
Locations: Tom Baker Cancer Centre, Calgary, Alberta, Canada
Ottawa General Hospital, Ottawa, Ontario, Canada
Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
Status: Completed
Last Changed: Sep 27, 2012
First Received: Jan 22, 2010
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): Rituximab
Locations: Samsung Medical Center, Seoul, Korea, Republic of
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
Status: Completed
Last Changed: Mar 07, 2018
First Received: Jan 11, 2013
Disease(s): Relapsed/Refractory B-cell Lymphoma
Intervention(s): CC-292 + lenalidomide
Locations: Hopital henri mondor, Créteil, France
CHU de Lille, Lille, France
Institut Paoli Calmette, Marseille, France
CHU de Nantes, Nantes, France
CHU Lyon Sud, Pierre Bénite, France
... and 2 other locations.
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status: Active, not recruiting
Last Changed: Nov 13, 2019
First Received: Apr 26, 2016
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): AZD 2014, Rituximab
Locations: Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Royal Liverpool University Hospital, Liverpool, United Kingdom
University College London Hospitals, London, United Kingdom
Guys Hospital, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
... and 5 other locations.
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 30, 2019
First Received: Jun 28, 2019
Disease(s): Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Intervention(s): TQB2450
Locations: Peking University First Hospital, Beijing, Beijing, China
Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijin, Beijing, China
Peking Hospital, Beijin, Beijing, China
... and 14 other locations.
A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Sep 19, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Mosunetuzumab, Tocilizumab
Locations: University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica, California, United States
University of Miami Sylvester Comprehensive Center, Miami, Florida, United States
Moffitt Cancer Center Screening and Prevention, Tampa, Florida, United States
Rush University Medical Center; Rush University Cancer Center, Chicago, Illinois, United States
Fort Wayne Medical Institute, Fort Wayne, Indiana, United States
... and 29 other locations.
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Completed
Last Changed: Nov 25, 2019
First Received: Sep 09, 2010
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide
Locations: Providence St Joseph Medical Center/Cancer Center, Burbank, California, United States
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
Emory University, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Rush University Medical Center, Chicago, Illinois, United States
... and 53 other locations.